Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy

Myung-Won Lee, MD*, Hyewon Ryu, MD*, Ik-Chan Song, MD*, Hwan-Jung Yun, MD*, Deog-Yeon Jo, MD*, Young Bok Ko, MDb,*, Hyo-Jin Lee, MDa,*

Abstract
The aim of this study was to evaluate the outcomes of patients with advanced or recurrent ovarian cancer treated with cisplatin combined with topotecan as second- or higher-line palliative chemotherapy. We retrospectively reviewed the medical records of patients with advanced or recurrent ovarian cancer, who were treated with cisplatin (50 mg/m² on day 1) and topotecan (0.75 mg/m² on days 1–3). Treatment response, progression-free survival (PFS) and overall survival (OS) were analyzed, and laboratory data were reviewed to evaluate toxicities.

Thirty one patients were treated with cisplatin and topotecan. The objective response rate (ORR) was 22.6%, and the disease control rate (DCR) was 61.3%. The median PFS was 3.7 months (95% confidence interval [CI], 2.3–5.2 months) and the median OS was 44.5 months (95% CI, 35.5–53.5 months). The ORR (33.3% vs. 0%; \( P < .012 \)) was significantly better in the platinum-sensitive group compared to the platinum-resistant group. The median PFS was significantly longer in the platinum-sensitive group compared to the platinum-resistant group (7.7 vs. 2.5 months; \( P < .001 \)), and the median OS was also significantly longer in the platinum-sensitive group (46.6 vs. 19.3 months; \( P < .001 \)). Almost all of the patients reported some degree of hematological toxicity. A high rate of grade 3–4 neutropenia (67.1%) was observed. Grade 3–4 thrombocytopenia (41.9%) and febrile neutropenia (19.4%) were also seen.

The results showed that cisplatin combined with topotecan, as second- or higher-line palliative chemotherapy for patients with advanced or recurrent ovarian cancer, might be effective, especially in the platinum-sensitive group. However, attention should be paid to the high hematological toxicity associated with this drug combination.

Abbreviations: ANC = absolute neutrophil count, CI = confidence interval, CR = complete response, DCR = disease control rate, DNA = deoxyribonucleic acid, G-CSF = granulocyte colony stimulating factor, ORR = overall response rate, OS = overall survival, PARP = poly ADP-ribose polymerase, PD = progressive disease, PFS = progression-free survival, PR = partial response, RECIST = response evaluation criteria in solid tumor, SD = stable disease, UNL = upper limit of normal, VEGF = vascular endothelial growth factor.

Keywords: cisplatin, ovarian cancer, palliative chemotherapy, topotecan

1. Introduction

Ovarian cancer is the third most common, and second most lethal, gynecological malignancy in the world.[1] Because ovarian cancer usually lacks distinct symptoms, and there are no effective screening tools in the early stage, more than 70% of patients are diagnosed with the disease in advanced stages. Thus, most ovarian cancers are incurable, and treatments focus on palliation of disease to slow its progress, increase the patients lifespan and improve quality of life. Due to gradual improvements in

Editor: Eric Bush.

This work was in part supported by the National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MSIP) (No. 2017R1A5A2015385). The authors report no conflicts of interest.

Supplemental Digital Content is available for this article.

* Department of Internal Medicine, Department of Obstetrics and Gynecology, Chungnam National University College of Medicine, Daejeon, Republic of Korea.

† Correspondence: Hyo-Jin Lee, Department of Internal Medicine, Chungnam National University College of Medicine, 266 Munhwa-ro, Jung-gu, Daejeon 35015, Republic of Korea. (e-mail: cymed@cnu.ac.kr) and Young Bok Ko, Department of Obstetrics and Gynecology, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea (e-mail: koyoung@cnuh.co.kr).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Lee MW, Ryu H, Song IC, Yun HJ, Jo DY, Ko YB, Lee HJ. Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy. Medicine 2020;99(17):e19931.

Received: 20 December 2019 / Received in final form: 26 February 2020 / Accepted: 17 March 2020
http://dx.doi.org/10.1097/MD.0000000000019931
treatments and the development of new drugs, ovarian cancer can now be managed like a chronic disease.[2,3]

In advanced ovarian cancer, the standard treatment is maximal debulking surgery to remove all visible lesions, followed by chemotherapy.[4,5] For almost 40 years, first-line chemotherapy regimens have usually been based on platinum doublet chemotherapy. A previous study demonstrated a significant increase in survival when paclitaxel was used in combination with platinum,[6] and platinum/taxane doublet is now firmly established as the first-line chemotherapy regimen.[7]

The water-soluble camptothecin analog topotecan is a cytotoxic agent that inhibits topoisomerase I and cleaves double-stranded deoxyribonucleic acid (DNA) during replication in the S phase, leading to cell death.[8] Several prior studies have revealed that topotecan has efficacy in the treatment of recurrent ovarian cancer.[9–13] Topotecan monotherapy has proven usefulness in patients with ovarian cancer, especially in platinum resistant group. For this reason, topotecan monotherapy is recommended in NCCN guidelines as one of the treatment option in platinum resistant ovarian cancer.[14] Cisplatin is platinum-based drug as carboplatin, which is used for the treatment of ovarian cancer, particularly cisplatin alone or in combination with gemcitabine as a treatment option for platinum sensitive ovarian cancer.[14] However, there are few data on the efficacy of cisplatin and topotecan combination regimen in ovarian cancer patients. In a first-line setting, Hoskins et al[15] reported the outcomes of cisplatin and topotecan combination therapy in advanced ovarian cancer, in a phase III randomized study comparing sequential cisplatin-topotecan and carboplatin-paclitaxel with carboplatin-paclitaxel. The results showed similar efficacy between the 2 groups, although toxicity was more severe in the cisplatin-topotecan group. Likewise, few data exist regarding the use of cisplatin combined with topotecan as second- or higher-line palliative chemotherapy in patients with advanced or recurrent ovarian cancer, even though this regimen could be an option for the treatment of advanced or recurrent ovarian cancer.[15–17] Against this background, we evaluated the clinical outcomes of advanced ovarian cancer patients treated with cisplatin combined with topotecan as second- or higher-line palliative therapy.

2. Methods

2.1. Patients

We collected and reviewed the medical records of patients diagnosed with advanced or relapsed ovarian cancer, and who were treated with cisplatin plus topotecan as a second- or higher-line palliative chemotherapy from March 2009 to June 2019 at Chungnam National University Hospital, Daejeon, Republic of Korea. We included patients ≥ 18 years of age with histologically or cytologically confirmed advanced or relapsed ovarian cancer. Other inclusion criteria included the presence of at least 1 measurable lesion according to the Response Evaluation Criteria in Solid Tumor (RECIST, version 1.1) criteria, an Eastern Cooperative Oncology Group performance score ≤ 2, previous treatment with at least 1 palliative systemic chemotherapy regimen, an absolute neutrophil count (ANC) ≥ 1500/ml and platelet count ≥ 100,000/ml, a serum creatinine level ≤ 1.5-fold the institutional upper limit of normal (ULN), a serum bilirubin level ≤ 1.5-fold the ULN, and an alkaline phosphatase level ≤ 2.5-fold the ULN. We excluded patients who had other malignancies within the last 5 years, patients who had previously received non-cytotoxic therapies (e.g., vascular endothelial growth factor [VEGF] or poly ADP-ribose polymerase [PARP] inhibitor monotherapy), patients who had not received cytoreductive surgery, patients requiring hospital admission for active bleeding and central nervous system disease, and patients who have active infection requiring systemic therapy at the initiation of the study treatment. Other exclusion criteria included significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure, or uncontrolled arrhythmias), pregnancy or nursing, or a major surgical procedure within the last 30 days. This study was approved by the Institutional Review Board of Chungnam National University Hospital.

2.2. Treatment

The patients were treated with cisplatin (50 mg/m² for 1 day) and topotecan (0.75 mg/m² for 3 days) and the cycles were repeated every 21 days. The cycles were delayed if the ANC was < 1500/ml, and/or the platelet count was < 100,000/ml on the proposed day of treatment. All patients received prophylactic medication for chemotherapy-induced nausea/vomiting. Granulocyte colony-stimulating factor (G-CSF) was administered to patients with ANC < 500/ml or febrile neutropenia. Chemotherapy was continued until disease progression, unacceptable toxicity, or patient refusal (maximum of 6 cycles).

2.3. Response and toxicity assessment

Response evaluations were performed according to clinical assessments and imaging studies, after every 2 or 3 cycles, in the absence of overt progression. The treatment response was classified as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) according to the RECIST criteria (version 1.1), and toxicity was evaluated based on the NCI Common Toxicity Criteria (CTC; version 5.0).

2.4. Statistical analysis

Basic descriptive statistics were obtained, including medians with ranges. Differences between groups were tested using the Chi-Squared test for categorical variables. Progression-free survival (PFS) was defined as the time between the first administration of chemotherapy and the date of tumor progression. Overall survival (OS) was defined as the time between the first administration of chemotherapy and the date of last contact or death. PFS and OS were estimated using the Kaplan–Meier method with the log-rank test. A P value < .05 was considered significant. SPSS statistical software for Windows (version 25.0; SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.

3. Results

3.1. Patient population

Thirty one patients with advanced or relapsed ovarian cancer were treated with cisplatin combined with topotecan as a second- or higher-line palliative chemotherapy. The median patient age was 59 years (range: 44–78 years). The histological subtypes were as follows:

- serous carcinoma (n = 20),
- transitional cell carcinoma (n = 2),
• mucinous carcinoma (n=2),
• clear cell carcinoma (n=2), and others (n=5).

All of the patients had undergone platinum-based cytotoxic chemotherapy before the study treatment. Platinum sensitivity was measured from the time of completion of platinum-based adjuvant chemotherapy to disease progression, and the intersection was 6 months. Ten patients (32.3%) were in the platinum-resistant group, and 21 were (67.7%) in the platinum-sensitive group (Table 1).

### Table 1

| Characteristics          | No. (%) |
|--------------------------|---------|
| Total number             | 31      |
| Age (y; median, range)   | 59 (44–78) |
| Histological type        |         |
| Serous carcinoma         | 20 (64.5) |
| Transitional cell carcinoma | 2 (6.5) |
| Mucinous carcinoma       | 2 (6.5) |
| Clear cell carcinoma     | 2 (6.5) |
| Others                   | 5 (16.1) |
| Platinum sensitivity     |         |
| Platinum-sensitive       | 21 (67.7) |
| Platinum-resistant       | 10 (32.3) |
| No. prior regimens       |         |
| 1                        | 9 (29.0) |
| 2                        | 12 (38.7) |
| 3                        | 8 (25.8) |
| ≥4                       | 2 (6.5) |

3.2. Tumor responses

CR was observed in no cases, while a PR was observed in 7 (22.6%) patients. SD was observed in 12 (38.7%) patients, and PD was observed in 12 (38.7%) patients. The objective response rate (ORR) was 22.6% and the disease control rate (DCR) was 61.3% (Table 2). The ORR (33.3% vs 0%; \( P = .012 \)) was significantly better in the platinum-sensitive group compared to the platinum-resistant group (Table 2). The tumor response according to number of prior regimens was not significantly different, although the ORR (33.3% vs 18.2%; \( P = .439 \)) tended to be higher in the patients treated with 1 prior regimen (Supplementary Table 1, http://links.lww.com/MD/E112). Fifteen patients had been retreated with paclitaxel/carboplatin after recurrence or progression following initial cytoreductive surgery and adjuvant chemotherapy. Among them, 12 (80.0%) patients showed at least PR to first-line paclitaxel/carboplatin (responder), and 3 (20.0%) patients did not show any tumor response (non-responder). The ORR was higher in the responder group compared with the non-responder group (41.7% vs 0%; \( P = .016 \)), and the DCR was also better in the responder group (83.3% vs 0%; \( P = .004 \)) (Supplementary Table 2, http://links.lww.com/MD/E112).

### Table 2

| Response | No. (%) |
|----------|---------|
| CR       | 0 (0)   |
| PR       | 7 (22.6) |
| SD       | 12 (38.7) |
| PD       | 12 (38.7) |
| ORR      | 7 (22.6) |
| DCR      | 19 (61.3) |

CR = complete response, PD = progressive disease, PR = partial response, SD = stable disease, ORR = objective response rate, DCR = disease control rate.

3.3. Survival outcomes

In all patients, the median PFS was 3.7 months (95% confidence interval [CI], 2.3–5.2) (Fig. 1) and the median OS was 44.5 months (95% CI, 35.5–53.3) (Fig. 2). The median PFS was significantly longer in the platinum-sensitive group compared to the platinum-resistant group (7.7 vs 2.5 months; \( P < .001 \)) (Fig. 3), and the median OS was also significantly longer in the platinum-sensitive group (46.6 vs 19.3 months; \( P < .001 \)) (Fig. 4). The median PFS was longer in the responder group compared with the non-responder group (7.7 vs 2.5 months; \( P < .001 \)) (Supplementary Fig. 1, http://links.lww.com/MD/E112), and the median OS was also longer in the responder group (46.6 vs 19.3 months; \( P < .001 \)) (Supplementary Fig. 2, http://links.lww.com/MD/E112).

3.4. Safety profiles

A total of 132 cycles of cisplatin and topotecan combination treatment were administered (median, 4.3 cycles/patient; range: 1–6 cycles/patient). Almost all of the patients reported some degree of hematological toxicity at least once. The rate of neutropenia was 100% for any grade, and 87.1% for grade 3. The rate of thrombocytopenia was 67.7% for any grade and 41.9% for grade 3–4. The rate of anemia was 96.8% for any grade and 77.4% for grades 3–4. Febrile neutropenia developed in 6 (19.4%) patients, and no patients died due to febrile neutropenia. For any grades, non-hematological toxicities included increased levels of creatinine in 3.2% of cases, alanine aminotransferase in 25.8% and bilirubin in 12.9%. No non-hematological toxicities were seen in those of grade 3–4 (Table 4).

### Table 3

| Response | Platinum-resistant No. (%) | Platinum-sensitive No. (%) | \( P \)-value |
|----------|----------------------------|---------------------------|-------------|
| CR       | 0 (0)                      | 0 (0)                     | .29         |
| PR       | 0 (0)                      | 7 (33.3)                  |            |
| SD       | 4 (40.0)                   | 8 (38.1)                  |            |
| PD       | 6 (60.0)                   | 6 (28.6)                  |            |
| ORR      | 0 (0)                      | 7 (33.3)                  | .012        |
| DCR      | 4 (40.0)                   | 15 (71.4)                 | .005        |

CR = complete response, PD = progressive disease, PR = partial response, SD = stable disease, ORR = objective response rate, DCR = disease control rate.

4. Discussion

The initial treatment for advanced ovarian cancer is well established, i.e., cytoreductive surgery followed by platinum plus taxane combination chemotherapy. The aim of surgery is to achieve complete resection of macroscopic residues, where complete resection of all macroscopic disease has been shown to be the single most important independent prognostic factor in advanced ovarian cancer.[18] After surgery, patients are treated with platinum and taxane combination regimes for 6 cycles.
However, even with successful front-line treatment, most patients relapse and about 50% to 80% ultimately require salvage therapy.\textsuperscript{[16]} Therefore, additional palliative chemotherapy is inevitable, and in these cases the palliative chemotherapy regimen is determined by platinum sensitivity.\textsuperscript{[19]}

Platinum sensitivity is one of the most important factors in palliative chemotherapy. Platinum-resistant disease is defined as progression within 6 months of the last platinum-containing regimen, while platinum-sensitive disease has been defined as progression after 6 months. Patients showing recurrence within 6 to 12 months may be reclassified as partially sensitive, and those experiencing relapse after 12 months as highly sensitive.\textsuperscript{[20,21]} In platinum-sensitive patients, a combination treatment such as cisplatin or carboplatin with paclitaxel, gemcitabine, or
Pegylated liposomal doxorubicin is generally used. Most of these drugs are associated with a PFS of 12 to 15 months.[7,19] On the other hand, platinum-resistant patients have a poor PFS. In these cases, the standard treatment is not well established but mainly monotherapies, such as pegylated liposomal doxorubicin and topotecan, are used.[7]

Recent therapeutic approaches include the addition of bevacizumab to conventional chemo-regimens and weekly dose-dense paclitaxel therapy; these have been shown to increase OS and are increasingly being used as first-line palliative chemotherapies instead of the existing standard therapies.[22–25] In addition, PARP inhibitors, such as olaparib, are being used in palliative therapy for recurrent ovarian cancer.[26] Although there are many options to choose from, ovarian cancer patients have a relatively long life, so treating them with new drug combinations is still important.[19]
As mentioned earlier, a prior study showed non-inferiority of a combination of cisplatin and topotecan as a first-line therapy in advanced ovarian cancer compared to carboplatin-paclitaxel.\[15]\n
The patients in that phase III study were administered cisplatin 50mg/m\(^2\) on day 1 and topotecan 0.75mg/m\(^2\) for 5 consecutive days. The patients in the study group had substantially higher myelotoxicity than those in the control group; specifically, 85% had grade 4 granulocytopenia and 22% had febrile neutropenia or infection with grade 3–4 neutropenia.\[15]\n
Another study reported the effect of cisplatin combined with topotecan as third-or higher-line palliative chemotherapy.\[16]\n
In that study, 1.0mg/m\(^2\) of topotecan was administered for 5 consecutive days and 50mg/m\(^2\) of cisplatin on day 1. The dose of topotecan was reduced by 0.25mg/m\(^2\)/day if grade 3–4 toxicity developed within 14 days. The study showed an ORR of 30%, but 90% of the patients had grade 3–4 neutropenia and 63% had thrombocytopenia.\[16]\n
Another small phase II study (n=15) used 0.6mg/m\(^2\)/day of topotecan for 5 days and 50mg/m\(^2\) of cisplatin on day 1, as third-or higher-line chemotherapy for the treatment of recurrent ovarian cancer.\[17]\n
In this study, the ORR was 13.3% and grade 4 thrombocytopenia and neutropenia occurred in 30% and 45% of patients, respectively. Although this study reported a relatively tolerable toxicity profile, the response rate was relatively low compared to other studies.\[17]\n
Thus it is important to reduce toxicity while maintaining efficacy. One way to ameliorate hematologic toxicity is to use a different administration schedule.\[27,28]\n
In support of this strategy, in studies on uterine cervical cancer patients, 50 mg/m\(^2\) cisplatin for 1 day and 0.75 mg/m\(^2\) topotecan for 3 days was used as the standard dose.\[18,29]\n
In these studies, 49.1% to 70% of the patients had grade 3–4 neutropenia and 16.3% to 31.3% had grade 3–4 thrombocytopenia; however, in almost all cases, the cytopenia was tolerable and manageable.\[18,29]\n
Although these results were obtained in the context of cervical cancer and not ovarian cancer, the relatively tolerable toxicity prompted speculation that this regimen could be used in ovarian cancer.

In this retrospective, single-center study, the combination of cisplatin and topotecan, as second- or higher-line palliative chemotherapy, showed clinical efficacy in women with recurrent ovarian cancer. The ORR was 22.6% and the DCR was 61.3%, similar to other second-line chemotherapy regimens.\[30–32]\n
The median PFS and OS were 3.7 and 44.5 months, respectively, thus also indicating similar efficacy to other second-line chemotherapy regimens.\[30–32]\n
The effect was more significant in the platinum-sensitive group than the platinum-resistant group, with an ORR of 33.3% and 0% and median PFS of 7.7 and 2.5 months, respectively. However, hematologic toxicity occurred in almost all of the patients. Specifically, 87.1% had grade 3 or higher neutropenia, 41.9% had grade 3 or higher thrombocytopenia, and 19.4% had febrile neutropenia. Fortunately, the cases showing toxicity were well managed via G-CSF administration, antibiotics and best supportive care, although it is strongly suggested that the condition of the patient should be considered very carefully before drug administration.

This study had several limitations. First, the number of patients assessed was low, at 31, which limited the statistical power. Second, as a result of the retrospective design, several types of bias affected the results pertaining to the effects and side effects of the combination regimen. Third, this study was a single-center study, so the patient population was relatively homogeneous. Finally, data on patient-reported outcomes, such as quality of life, were not available. Hence a well-designed and controlled prospective study is needed.

In conclusion, although the small number of patients and retrospective nature of this study represent major limitations, the use of cisplatin combined with topotecan, as second or higher-line palliative chemotherapy for advanced or recurrent ovarian cancer patients, might be effective, especially in platinum-sensitive patients. However, clinicians should manage the patient carefully due to the high hematological toxicity of this regimen.

**Author contributions**

**Conceptualization:** Hyo Jin Lee, Young Bok Ko.

**Data curation:** Myung-Won Lee, Ik-Chan Song.

**Funding acquisition:** Hyo Jin Lee.

**Investigation:** Young Bok Ko, Hwan-Jung Yun.

**Methodology:** Myung-Won Lee, Hyewon Ryu.

**Supervision:** Hyo Jin Lee, Young Bok Ko.

**Writing – original draft:** Myung-Won Lee, Ik-Chan Song.

**Writing – review & editing:** Deog-Yeon Jo, Hyo Jin Lee, Young Bok Ko.

Hyo Jin Lee orcid: 0000-0001-8378-3001.

**References**

1. International Agency for Research on Cancer. Global cancer statistics. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (accessed Sep 16, 2019).

2. Cortez AJ, Tuderj P, Kujawa KA, et al. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 2018;81:17–38.

3. Song YS, Kim HS, Aoki D, et al. Ovarian cancer. Biomed Res Int 2014;2014:764323.

4. Kohoe S, Hook J, Nankivel M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015;386:249–57.

5. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943–53.

6. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6.

7. Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. Lancet 2014;384:1376–88.

8. Moon JY, Song IC, Ko YB, et al. The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer. Medicine (Baltimore) 2018;97:e15346.

9. Ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183–93.

10. Creemers Gj, Bols G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056–61.
[11] Creemers GJ, Bolis G, Gore M, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 1998;16:2233–7.

[12] Bookman MA, Malmström H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345–52.

[13] Kudelka AP, Tresukosol D, Edwards CI, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1352–7.

[14] National Comprehensive Cancer Network. Ovarian Cancer Including Fallopian tube cancer and Primary Peritoneal Cancer (Version 3.2019). http://www.nccn.org/professionals/physician_gls/pdf/bone.pdf. Accessed November 26, 2019.

[15] Hoskins P, Vergote I, Cervantes A, et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 2010;102:1547–56.

[16] Kim HS, Park NH, Kang S, et al. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. J Obstet Gynaecol Res 2010;36:86–93.

[17] Ghamande SA, Priver MS. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study. J Surg Oncol 1999;72:162–6.

[18] Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 2019;30:672–705.

[19] Hall M, Rustin G. Recurrent ovarian cancer: when and how to treat. Curr Oncol Rep 2011;13:459–71.

[20] Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389–93.

[21] Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997;8:963–8.

[22] Grunewald T, Ledermann JA. Targeted therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2017;41:139–52.

[23] Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 2015;139:10–6.

[24] Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carcnonplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017;18:779–91.

[25] Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013;14:1020–6.

[26] Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382–92.

[27] Kim HS, Lee JY, Lee SJ, et al. A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer. BMC Urol 2017;17:63.

[28] Lee JL, Kim JE, Ahn JH, et al. Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone refractory prostate adenocarcinoma: single institutional study in Korea. Cancer Res Treat 2010;42:12–7.

[29] Long HJ3rd, Bundy BN, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626–33.

[30] Herzog TJ, Powell MA, Rader JS, et al. Phase II evaluation of topotecan and nabumetone in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol 2008;111:467–73.

[31] Abushahin F, Singh DK, Lurain JR, et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol 2008;108:51–7.

[32] Herzog TJ, Sill MW, Walker JL, et al. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol 2011;120:454–8.